Key Highlights
- Brainomix and Boehringer Ingelheim join forces to improve fibrosing lung disease care.
- Brainomix 360 e-Lung to be deployed in leading US pulmonology centers.
- Early diagnosis and treatment for fibrosing lung disease targeted.
- FDA-cleared e-Lung software aids in diagnosis and treatment pathways.
- Real-world evidence to validate the AI-driven approach.
Source: PR Newswire
Notable Quotes
- “There is an urgent need to improve the identification of people with fibrosing lung disease. This will enable earlier access to specialist care and the opportunity for faster initiation of treatment, which can slow the worsening of the disease.” — Dr. Michalis Papadakis, CEO and Co-Founder at Brainomix
- “We believe that Brainomix 360 e-Lung has the potential to revolutionize the diagnostic landscape and thereby enable earlier treatment decisions at a pivotal stage of the patient’s journey.” — Ioannis Sapountzis, Head of Global Therapeutic Areas at Boehringer Ingelheim
SoHC's Take
The partnership between Brainomix and Boehringer Ingelheim represents a significant advancement in the care of patients with fibrosing lung disease. By leveraging Brainomix’s AI-driven imaging technology, this collaboration aims to address the critical need for early and accurate diagnosis, which is essential for timely treatment initiation. The deployment of Brainomix 360 e-Lung across US pulmonology centers will not only streamline the diagnostic process but also potentially improve patient outcomes by enabling faster access to care. This initiative underscores the transformative power of AI in healthcare and highlights the commitment of both organizations to enhancing patient care through innovative solutions.
